Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

Go back to Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

Hims and Hers (HIMS) PT Raised to $28 at BofA Securities

May 6, 2025 6:59 AM EDT

BofA Securities analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $28.00 (from $26.00) while maintaining a Underperform rating.

The analyst comments "Following this quarters earnings, we see a wider range of outcomes for full year revenue (link to our first take here). In the first scenario, if HIMS were to grow its... More

Hims and Hers (HIMS) PT Raised to $42 at Leerink Partners

May 6, 2025 6:19 AM EDT

Leerink Partners analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $42.00 (from $40.00) while maintaining a Market Perform rating.

The analyst comments "HIMS's 2Q earnings touched on a number of key flash points as the company shifts to the next generation of GLP-1... More

BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS)

May 6, 2025 4:58 AM EDT

BofA Securities analyst Michael Cherny reiterated an Underperform rating and $26.00 price target on Hims and Hers (NYSE: HIMS).

The analyst comments "HIMS reported a strong quarter, with revenue of $586MM well ahead of the guidance/consensus and slightly ahead of BofAs estimate of $583.1MM. Second quarter... More